Perceptive Advisors Llc Buys Agios Pharmaceuticals Inc, Provention Bio Inc, Quotient, Sells Dova Pharmaceuticals Inc, Solid Biosciences Inc, Spark Therapeutics Inc

• New Purchases: AGIO, ARVN, ANAB, AUPH, RVNC, MORF, COLL, ISEE, NLTX, ABEO, RYTM, TXMD, PHR, AXNX, SWAV, DRNA, DCPH, ARAV, KRMD, OPTN, CNST, ACAD, KRTX, PRTO, TORC, AVDL,
• Added Positions: KOD, PRVB, QTNT, ZGNX, TNDM, ATNX, DBVT, MTEM, KDMN, RCKT, MYOK, SWTX, FOLD, VCRA, AGRX, CERN, UROV, HCAT, TWST, BIO, EIDX, ADPT,
• Reduced Positions: NBIX, IOVA, BPMC, NVRO, NVTA, MRTX, AMRN, YMAB, TPTX, RTRX, SIC, EHTH, ESTA, ATEC, MNTA, VAPO, CNCE,
• Sold Out: DOVA, SLDB, ONCE, MMSI, GX1N, CBAY, MEIP, ORTX, CORV, SGEN, AXSM, MDCO, MEDP, RARX, GTHX, ALNA, ALLK, CFMS,

For the details of PERCEPTIVE ADVISORS LLC's stock buys and sells, go to https://www.gurufocus.com/guru/perceptive+advisors+llc/current-portfolio/portfolio

1. Global Blood Therapeutics Inc (GBT) - 5,865,726 shares, 9.60% of the total portfolio. Shares reduced by 0.17%
2. Mirati Therapeutics Inc (MRTX) - 3,203,406 shares, 8.50% of the total portfolio. Shares reduced by 3.35%
3. Neurocrine Biosciences Inc (NBIX) - 3,612,554 shares, 8.00% of the total portfolio. Shares reduced by 11.02%
4. Kodiak Sciences Inc (KOD) - 3,663,557 shares, 5.43% of the total portfolio. Shares added by 16.85%
5. Iovance Biotherapeutics Inc (IOVA) - 9,416,202 shares, 5.37% of the total portfolio. Shares reduced by 14.51%

Perceptive Advisors Llc initiated holding in Agios Pharmaceuticals Inc. The purchase prices were between $30.08 and $50.59, with an estimated average price of $38.07. The stock is now traded at around $53.04. The impact to a portfolio due to this purchase was 0.89%. The holding were 900,000 shares as of .

Perceptive Advisors Llc initiated holding in Arvinas Inc. The purchase prices were between $15.39 and $44.38, with an estimated average price of $29.74. The stock is now traded at around $50.86. The impact to a portfolio due to this purchase was 0.34%. The holding were 400,000 shares as of .

Perceptive Advisors Llc initiated holding in AnaptysBio Inc. The purchase prices were between $10.18 and $38.96, with an estimated average price of $23.27. The stock is now traded at around $15.53. The impact to a portfolio due to this purchase was 0.33%. The holding were 1,000,000 shares as of .

Perceptive Advisors Llc initiated holding in Aurinia Pharmaceuticals Inc. The purchase prices were between $3.88 and $21.42, with an estimated average price of $9.42. The stock is now traded at around $20.03. The impact to a portfolio due to this purchase was 0.3%. The holding were 716,666 shares as of .

Perceptive Advisors Llc initiated holding in Revance Therapeutics Inc. The purchase prices were between $11.66 and $20.15, with an estimated average price of $15.6. The stock is now traded at around $26.68. The impact to a portfolio due to this purchase was 0.27%. The holding were 820,377 shares as of .

Perceptive Advisors Llc initiated holding in Morphic Holding Inc. The purchase prices were between $13.02 and $19.5, with an estimated average price of $15.61. The stock is now traded at around $13.95. The impact to a portfolio due to this purchase was 0.23%. The holding were 650,000 shares as of .

Perceptive Advisors Llc added to a holding in Provention Bio Inc by 338.46%. The purchase prices were between $5.84 and $14.9, with an estimated average price of $9.04. The stock is now traded at around $15.40. The impact to a portfolio due to this purchase was 0.69%. The holding were 2,921,574 shares as of .

Perceptive Advisors Llc added to a holding in Quotient Ltd by 23.17%. The purchase prices were between $7.07 and $9.51, with an estimated average price of $8.31. The stock is now traded at around $7.29. The impact to a portfolio due to this purchase was 0.49%. The holding were 13,289,054 shares as of .

Perceptive Advisors Llc added to a holding in Tandem Diabetes Care Inc by 4727.16%. The purchase prices were between $53.13 and $71.19, with an estimated average price of $61.87. The stock is now traded at around $90.04. The impact to a portfolio due to this purchase was 0.37%. The holding were 310,000 shares as of .

Perceptive Advisors Llc added to a holding in DBV Technologies SA by 21.02%. The purchase prices were between $6.75 and $11.15, with an estimated average price of $8.02. The stock is now traded at around $9.67. The impact to a portfolio due to this purchase was 0.17%. The holding were 4,367,809 shares as of .

Perceptive Advisors Llc added to a holding in Molecular Templates Inc by 25.33%. The purchase prices were between $6.44 and $14.21, with an estimated average price of $9.72. The stock is now traded at around $15.58. The impact to a portfolio due to this purchase was 0.14%. The holding were 2,474,133 shares as of .

Perceptive Advisors Llc added to a holding in Vocera Communications Inc by 197.00%. The purchase prices were between $19.12 and $24.89, with an estimated average price of $21.91. The stock is now traded at around $25.80. The impact to a portfolio due to this purchase was 0.09%. The holding were 296,420 shares as of .

Perceptive Advisors Llc sold out a holding in Dova Pharmaceuticals Inc. The sale prices were between $27.98 and $28.51, with an estimated average price of $28.18.

Perceptive Advisors Llc sold out a holding in Solid Biosciences Inc. The sale prices were between $2.82 and $12.9, with an estimated average price of $7.22.

Perceptive Advisors Llc sold out a holding in Spark Therapeutics Inc. The sale prices were between $96.25 and $113.57, with an estimated average price of $107.51.

Perceptive Advisors Llc sold out a holding in Merit Medical Systems Inc. The sale prices were between $20.66 and $32.08, with an estimated average price of $28.67.

Perceptive Advisors Llc sold out a holding in Marker Therapeutics Inc. The sale prices were between $2.39 and $4.27, with an estimated average price of $3.23.

Perceptive Advisors Llc sold out a holding in CymaBay Therapeutics Inc. The sale prices were between $1.33 and $5.93, with an estimated average price of $3.68.

Perceptive Advisors Llc reduced to a holding in Blueprint Medicines Corp by 29.96%. The sale prices were between $66.73 and $82.59, with an estimated average price of $75.07. The stock is now traded at around $65.92. The impact to a portfolio due to this sale was -0.54%. Perceptive Advisors Llc still held 618,624 shares as of .

Perceptive Advisors Llc reduced to a holding in Nevro Corp by 21.63%. The sale prices were between $76.41 and $117.54, with an estimated average price of $99.76. The stock is now traded at around $144.31. The impact to a portfolio due to this sale was -0.5%. Perceptive Advisors Llc still held 763,886 shares as of .

Perceptive Advisors Llc reduced to a holding in Invitae Corp by 71.93%. The sale prices were between $15.02 and $20.57, with an estimated average price of $17.7. The stock is now traded at around $27.50. The impact to a portfolio due to this sale was -0.46%. Perceptive Advisors Llc still held 336,308 shares as of .

Perceptive Advisors Llc reduced to a holding in Y-mAbs Therapeutics Inc by 34.24%. The sale prices were between $23.81 and $33.78, with an estimated average price of $29.77. The stock is now traded at around $34.47. The impact to a portfolio due to this sale was -0.21%. Perceptive Advisors Llc still held 562,237 shares as of .

Perceptive Advisors Llc reduced to a holding in Turning Point Therapeutics Inc by 26.76%. The sale prices were between $35.56 and $63.25, with an estimated average price of $48.08. The stock is now traded at around $60.23. The impact to a portfolio due to this sale was -0.17%. Perceptive Advisors Llc still held 437,390 shares as of .

Perceptive Advisors Llc reduced to a holding in Select Interior Concepts Inc by 76.11%. The sale prices were between $8.92 and $12.65, with an estimated average price of $10.59. The stock is now traded at around $8.15. The impact to a portfolio due to this sale was -0.12%. Perceptive Advisors Llc still held 105,105 shares as of .